EBC-129

Investigational

EBC-129; EBC129

Target

N256-glycosylated CEACAM5 and CEACAM6 (shared tumor-specific glyco-epitope) · CEACAM5; CEACAM6

Sponsor

Experimental Drug Development Centre (EDDC), A*STAR Singapore

Indication

Pancreatic ductal adenocarcinoma (PDAC); advanced solid tumors

Target family

CEACAM family

RP2D dose

1.8 and 2.2 mg/kg

Once every 3 weeks (Q3W)RP2D

Multi-organ toxicity

Fingerprint & organ drill-down

Also reported

0%severity100%

Assessed · clear

true 0%

No data

never assessed

1 adverse-event term

Ocular

Any-grade

G3+

RP2D

sagittal schematic · Reversible

↳

Tissues shaded by reported adverse-event rate.

Cornea

Express.

Limbus

Express.

Conjunctiva

Express.

Lens

Express.

Retina / RPE

Express.

Dominant tissue

Hematologic

Surface subtype

None

Reversibility

Reversible

Reported ocular events

Ocular adverse events (any)0%

Per-trial detail

Adverse events by trial

NCT05701527 Phase 1 (Part A, all solid tumors)Phase 10.3–2.2 mg/kg Q3Wn=18PooledD

EBC-129 ESMO 2024 poster abstr 653P, Table 1 (TEAEs PT >10%, N=18)

21 adverse-event terms · 6 systems · expand a system below

GI6

Nausea

39%

7/18

Diarrhoea

22%G3+ 6%

4/18

Vomiting

17%G3+ 6%

3/18

Decreased appetite

11%

2/18

Abdominal pain upper

11%

2/18

Dyspepsia

11%

2/18

General5

Hematologic5

Hepatic2

Pulmonary2

Infusion1

Construct

Molecular anatomy

Antibody

IgG1

Humanized

Linker

Peptide

Cleavable

3.5

DAR

Payload

Monomethyl auristatin E (MMAE)

Microtubule polymerization inhibitor (tubulin-binding antimitotic)

Linker structureC28H40N6O7

Payload structureC39H67N5O7

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC

Antibody

Antibody & Fc engineering

Antibody

EBC-092

Isotype

IgG1

Origin

Humanized

Fc modifications

Glycoengineering

Effector silencing

FcγR binding

Retained

C1q binding

Retained

Target KD (nM)

Epitope / domain

Conformational glyco-epitope at N256-linked glycan on CEACAM5/CEACAM6

Linker & conjugation

Linker chemistry

Linker profile

Linker

Mc-Val-Cit-PABC (maleimidocaproyl-valine-citrulline-PABC)

Class

Peptide

Cleavage

Cleavable

Attachment

Cysteine (interchain)

Conjugation

Symmetry

DAR (mean)

3.5

DAR homogeneity

Plasma t½

Cleavage trigger

Cathepsin B (Val-Cit dipeptide)

Release control

Conditional

Hydrophilicity mask

None

Formula

C28H40N6O7

Linker MW

572.663 Da

Linker TPSA

200.03 Å²

Linker xLogP

0.6769

ADCdb linker

LIN0SQEDQ

In-vitro stability

Payload

Payload & physicochemistry

Payload profile

Payload

Monomethyl auristatin E (MMAE)

Class

Auristatin

Mechanism

Microtubule polymerization inhibitor (tubulin-binding antimitotic)

Released catabolite

MMAE (free monomethyl auristatin E)

Mechanistic subtype

Tubulin-auristatin

Stereochem / salt

Free base

Bystander

Yes

PAMPA rank

718 Da

XLogP3

4.1

logD₇.₄

2.55

TPSA

150 Å²

pKa

8.2 pKa

Charge pH 7.4

H-bond donors

H-bond acceptors

IC50 (HCEC)

Formula

C39H67N5O7

PubChem CID

11542188

ADCdb payload

PAY0FSXOW

Hydrophobicity · logD₇.₄

hydrophilic −2+2.55+4 lipophilic

Dosing & regimen

Dosing

RP2D dose

1.8 and 2.2 mg/kg

Schedule

Once every 3 weeks (Q3W)

Route

Fractionated

n at RP2D

Dose basis

TBW

Trial phase

Phase 1

Dose-OAE available

Yes

Tox summary basis

RP2D

Ocular & expression

Ocular profile & eye-tissue target expression

Target profile

OAE any-grade

0 %

OAE grade 3+

0 %

OAE data status

documented-absent

Severity (weighted)

Keratopathy

0 %

Conjunctival

Dry eye

Blurred vision

Dominant tissue

Hematologic

Surface subtype

None

Grading scale

CTCAE (unversioned)

Reversibility

Reversible

Target expression in eye tissues (HCA detection · HPA bulk)

Cornea (central)

Cornea (limbal)

Conjunctiva

RPE

Retina (HPA)

Cross-trial comparability · source-verified

Ascertainment: Systematic eye examsScale: CTCAE (unversioned)Denominator: RP2D

Dose & schedule → ocular toxicity · ocular AE (any-grade) by cohort

1.8-2.2 mg/kg

Q3W

· NCT05701527 Phase 1 (PDAC cohort)

1.8-2.2 mg/kg (overall safety population)

IV Q3W

n=58 · EBC-129 Ph1 PDAC subgroup (ASCO 2025)

Per-cohort rates from the per-trial extraction, sorted by dose. Cross-trial comparison is subject to ascertainment / scale differences (see comparability above) — e.g. an early symptom-driven trial can read lower than a later systematic-exam trial at a higher dose.

Ocular AE grading reference — interspecialty consensus · 6 scales + dose modification

Identity & registry

Identifiers, registry & notes

ADC id

ebc-129

Approval status

Investigational

Approval year

UniProt

P06731 (CEACAM5); P40199 (CEACAM6)

ADCdb ADC

DRG0QBQKB

ADCdb antibody

ADCdb target

TAR0CXRBX

Primary source

ASCO 2025 EBC-129 Phase 1 PDAC (JCO 43.16_suppl.4018; NCT05701527; OncLive/CancerNetwork/Targeted Oncology coverage)

Aliases & development codes

EBC-129; EBC129

Notes

EBC-129 is a first-in-class ADC targeting a tumor-specific N256-glycosylated epitope shared by CEACAM5 and CEACAM6, carrying an MMAE payload via a cathepsin-cleavable Mc-Val-Cit-PABC linker (DAR 3.5; ADCdb DRG0QBQKB). Phase 1 FIH (NCT05701527, EDDC sponsor) reported in advanced solid tumors with a heavily pretreated metastatic PDAC focus (n=21 PDAC across escalation+expansion; 58 total treated per Mirage/EBDC release). Doses 1.8/2.0/2.2 mg/kg Q3W; 1.8 and 2.2 mg/kg established as RP2Ds. Manageable safety: neutropenia 31.0% and infusion-related reactions 13.8% were the main TRAEs; neuropathy ~6%; no grade 5 events; no discontinuations for toxicity. Triage CONFIRMED explicit-zero ocular: OncLive/CancerNetwork coverage states "no ocular events reported," notable given MMAE ocular risk. FDA Fast Track granted for PDAC. Granular per-grade and per-PT toxicity tables (anemia, thrombocytopenia, nausea, hepatic) not available at abstract/press level. Antibody name and isotype undisclosed by ADCdb/sponsor. MMAE payload physchem from PubChem CID 11542188. Conference-abstract/press granularity, so low-frequency AEs (including any low-grade ocular) below reporting threshold cannot be fully excluded, but ocular was explicitly characterized as absent.